These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29788416)

  • 61. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
    Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
    J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion.
    de Carvalho JF; Dos Santos MNP; de Oliveira JMV; Lanty Silva ANS; de Araujo RPC; Cardozo JB
    Adv Rheumatol; 2018 Aug; 58(1):22. PubMed ID: 30657070
    [TBL] [Abstract][Full Text] [Related]  

  • 63. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
    Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
    Fiorino G; Manetti N; Armuzzi A; Orlando A; Variola A; Bonovas S; Bossa F; Maconi G; DʼIncà R; Lionetti P; Cantoro L; Fries W; Annunziata ML; Costa F; Terpin MM; Biancone L; Cortelezzi CC; Amato A; Ardizzone S; Danese S; Guidi L; Rizzuto G; Massella A; Andriulli A; Massari A; Lorenzon G; Ghione S; Kohn A; Ventra A; Annese V;
    Inflamm Bowel Dis; 2017 Feb; 23(2):233-243. PubMed ID: 28092307
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
    Checkley LA; Kristofek L; Kile S; Bolgar W
    Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Rapid Infliximab Infusion in the Pediatric Population.
    Munsel EJ; Bryan PJ; Binstadt BA; Bullock D; Correll CK; Downs EM; Hobday PM; Larson-Nath C; Sudel B; Vehe RK
    J Pediatr Pharmacol Ther; 2020; 25(8):705-708. PubMed ID: 33214781
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [PREMEDICATION WITH CORTICOSTEROIDS PRIOR TO IV INFLIXIMAB - A COMPARISON BETWEEN INFLAMMATORY BOWEL DISEASE (IBD) AND RHEUMATIC PATIENTS].
    Oshri D; Schwarz D; Vodonos A; Zimhony N; Abu-Shakra M; Zeller L
    Harefuah; 2019 Sep; 158(9):571-575. PubMed ID: 31507106
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases.
    Saxena P; Chen G; Jideh B; Collins G; Leong RW
    Expert Opin Biol Ther; 2014 Mar; 14(3):277-82. PubMed ID: 24359522
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
    McConnell J; Parvulescu-Codrea S; Behm B; Hill B; Dunkle E; Finke K; Snyder K; Tuskey A; Cox D; Woodward B
    World J Gastrointest Pharmacol Ther; 2012 Oct; 3(5):74-82. PubMed ID: 23515325
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Premedication prevents infusion reactions and improves retention rate during infliximab treatment.
    Bartoli F; Bruni C; Cometi L; Blagojevic J; Fiori G; Tofani L; Galluccio F; Furst DE; Matucci Cerinic M
    Clin Rheumatol; 2016 Nov; 35(11):2841-2845. PubMed ID: 27436188
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety, satisfaction and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease.
    Crane H; Wu N; Chan P; Nguyen P; Williams AJ; Ng W; Connor SJ
    Intern Med J; 2022 Dec; 52(12):2143-2149. PubMed ID: 34405958
    [TBL] [Abstract][Full Text] [Related]  

  • 74. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Verma AM; Patel A; Subramanian S; Smith PJ
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534
    [No Abstract]   [Full Text] [Related]  

  • 75. Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry.
    Choquette D; Faraawi R; Chow A; Rodrigues J; Bensen WJ; Nantel F
    J Rheumatol; 2015 Jul; 42(7):1105-11. PubMed ID: 26077415
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Outcomes for Standardized Home and Hospital-Based Infusions of Infliximab for Children With Inflammatory Bowel Disease.
    Gupta SR; Bricker J; Boyle BM; Maltz RM; Michel HK; Dotson JL
    J Pediatr Gastroenterol Nutr; 2023 Jun; 76(6):776-781. PubMed ID: 36930973
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
    Hilley P; Wong D; Ma R; Peterson A; De Cruz P
    Intern Med J; 2024 Jun; 54(6):970-979. PubMed ID: 38214034
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Use of infliximab in pediatric patients with inflammatory bowel disease.
    Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE
    Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions.
    Pauchard I; Nancey S; Hacard F; Williet N; Roblin X; Moussata D; Bérard F; Flourié B; Boschetti G
    Dig Dis; 2018; 36(6):417-426. PubMed ID: 30130790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.